Corvus Pharmaceuticals/$CRVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Corvus Pharmaceuticals
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Ticker
$CRVS
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
31
ISIN
US2210151005
Website
CRVS Metrics
BasicAdvanced
$322M
-
-$0.99
0.66
-
Price and volume
Market cap
$322M
Beta
0.66
52-week high
$9.28
52-week low
$1.78
Average daily volume
1M
Financial strength
Current ratio
4.903
Quick ratio
4.789
Long term debt to equity
2.338
Total debt to equity
2.338
Profitability
EBITDA (TTM)
-31.133
Management effectiveness
Return on assets (TTM)
-39.21%
Return on equity (TTM)
-100.13%
Valuation
Price to book
5.78
Price to tangible book (TTM)
5.78
Price to free cash flow (TTM)
-9.768
Free cash flow yield (TTM)
-10.24%
Free cash flow per share (TTM)
-42.79%
Growth
Earnings per share change (TTM)
93.07%
3-year earnings per share growth (CAGR)
3.72%
What the Analysts think about CRVS
Analyst ratings (Buy, Hold, Sell) for Corvus Pharmaceuticals stock.
Bulls say / Bears say
Corvus Pharmaceuticals' stock reached a 52-week high of $4.77, reflecting a 173.1% increase over the past year, indicating strong investor confidence in the company's pipeline and strategic initiatives. (Investing.com)
The company secured approximately $30.6 million through a securities purchase agreement, enhancing its financial position to support ongoing clinical programs. (Investing.com)
Oppenheimer raised its price target for Corvus Pharmaceuticals to $14.00, maintaining an 'Outperform' rating, reflecting positive analyst sentiment. (Techdows News)
Interim data from a Phase 1 trial evaluating soquelitinib in atopic dermatitis showed a favorable safety profile, but the stock experienced a decline following the announcement, suggesting market concerns about the trial's implications. (StockNews.com)
StockNews.com downgraded Corvus Pharmaceuticals from a 'hold' rating to a 'sell' rating, indicating potential concerns about the company's prospects. (Defense World)
Despite positive trial results, the stock's volatility and recent downgrades by analysts may indicate underlying risks and uncertainties in the company's future performance. (StockNews.com)
Data summarised monthly by Lightyear AI. Last updated on 13 Jun 2025.
CRVS Financial Performance
Revenues and expenses
CRVS Earnings Performance
Company profitability
CRVS News
AllArticlesVideos
3 Penny Stocks Wall Street Sees With 243% Upside
24/7 Wall Street·4 weeks ago
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
GlobeNewsWire·1 month ago
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Corvus Pharmaceuticals stock?
Corvus Pharmaceuticals (CRVS) has a market cap of $322M as of July 11, 2025.
What is the P/E ratio for Corvus Pharmaceuticals stock?
The price to earnings (P/E) ratio for Corvus Pharmaceuticals (CRVS) stock is 0 as of July 11, 2025.
Does Corvus Pharmaceuticals stock pay dividends?
No, Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Corvus Pharmaceuticals dividend payment date?
Corvus Pharmaceuticals (CRVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Corvus Pharmaceuticals?
Corvus Pharmaceuticals (CRVS) has a beta rating of 0.66. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.